Sofinnova Investments related stories
All articles and analysis
peHUB Wire: Wednesday, July 1, 2009Q2 Data Dump
- Catalyst Biosciences Partners with Wyeth, Deal Could Be Worth $500 Million+
Catalyst Biosciences Inc., a South San Francisco-based developer of engineered proteases, has signed an exclusive worldwide collaboration agreement with Wyeth (NYSE: WYE), related to Factor VIIa products to treat hemophilia and other bleeding conditions. Under terms of the deal, Catalyst will receive a $21 million up-front payment, with the potential to earn over $500 million via research funding and milestone payments. Catalyst previously had raised around $83 million, frfom firms like Burrill & Co., Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures.
- Funding European venture capital
The life of a VC on the fund raising trail has often been a tortuous one, never more so than in the midst of a recession. There are still capital pools to be tapped, however, but more efforts needs to be directed at loosening those purse strings.
- Streamazzo Raises €4 Million
Streamazzo SA, a Paris-based provider of rich application software platforms for mobile, has raised €4 million in new VC funding. Innovacom led the round, and was joined by return backers Sofinnova Partners, Sofinnova Ventures, Qualcomm, NTEC and GET Valorisation.
- peHUB Wire: Thursday, May 14, 2009
Thursday Throwback
- Week in deals, April 20, 2009
Summary of tech companies and other businesses that raised financing in North America in the past week
- peHUB Wire: Monday, April 13, 2009
A Federal VC Fund-of-Funds?
- Marinus Pharma Raises $20 Million
Marinus Pharmaceuticals Inc., a Branford, Conn.-based developer of neurological and psychiatric drugs, has raised $20 million in Series B funding. Return backers include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners. The company's lead candidate is for adults who suffer from partial onset seizures.
- Report: DiObix Shutting Down
DiObex Inc., a San Francisco-based drug company focused on metabolic disorders like Type II diabetes, has laid off all its employees and is looking to sell its assets, according to VentureWire. The company had raised around $50 million in VC funding, from firms like Inventages Venture Capital, Mitsui & Co., Pac-Link BioVentures, Domain Associates, Pequot Ventures and Sofinnova Ventures. www.diobex.com
- peHUB Wire: Wednesday, April 8, 2009
Random Ramblings